pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Boundless Bio, Inc. ($BOLD) · news · pharmadog
← back to Boundless Bio, Inc.
News mentioning $BOLD
54
stories
9h
Novartis projects slowed growth, pins hopes on billions in pipeline potential
biospace
10h
Regeneron racks up another first as FDA greenlights generalized myasthenia gravis RNA drug
biospace
13h
Sanders’ ‘Medicare for All’ plan accrues more liberal and moderate support in Congress
stat
2d
Why 2027 could be ‘Europe’s year to shine’: Panelists debate biotech funding at Fierce’s London event
fiercebiotech
3d
Opinion: Medical school should start after students take the Step 1 exam
stat
3d
J&J pays $2.2B upfront for Ollin to challenge Roche’s Vabysmo with phase 3 bispecific
fiercebiotech
6d
HHS pumps up to $25M into ibogaine, other psychotropic drugs on Veteran’s Day
biospace
8d
Without US action on China’s innovation blitz, biotech leaders see a Rust Belt future
biospace
10d
STAT+: Ionis Pharmaceuticals shares plummet after slow rollout of biotech’s triglyceride-lowering drug
stat
10d
STAT+: Bill Ackman’s bold plan to transform brain research
stat
10d
Details from Novartis’ failed cardiovascular trial offer ‘little silver lining’ for rivals
biospace
14d
Opinion: I’m a neurosurgeon. I’ve learned pain and suffering are very different things
stat
15d
6 potential blockbusters that could pave China’s path to 2030 ambitions
biospace
17d
FDA peptide policy risks undermining drug development and patient safety
biospace
22d
Lilly’s retatrutide trounces Novo’s Ozempic in diabetes, weight loss
biospace
27d
STAT+: Up and down the ladder: The latest comings and goings
stat
29d
STAT+: Pharmalittle: We’re reading about Mark Cuban eyeing rare disease drugs, a ketamine gold rush, and more
stat
29d
Nigeria identifies travel-related Ebola case
stat
29d
A counterintuitive way to build trust in measles vaccines and public health
stat
Oct 15, 26
Iambic, an AI drug discovery specialist, banks $150M in an IPO
biopharma dive
Oct 14, 26
FDA Launches the Rare Disease Framework Initiative to Develop a Holistic, Fit-For-Purpose Framework for Rare Disease Drug Development
fda press
Oct 9, 26
How Abogen went from COVID hype to a $7.8B Novartis deal
biospace
Oct 7, 26
Matchpoint nets $150M series B to take covalent med into clinic
fiercebiotech
Oct 6, 26
Opinion: Why the FDA should not approve an ineffective multicancer screening test
stat
Sep 21, 26
‘It’s actually very radical’: NIH debuts tool to help scientists navigate biomedical database
fiercebiotech
Sep 21, 26
Novo struggles to appease restive investors with consumer plans, blockbuster ambitions
fiercebiotech
Sep 17, 26
ARPA-H launches SPECTRA program, new autism research initiative
fiercebiotech
Sep 17, 26
After Novartis’ devastating M&A losses, long live the executive willing to try
biospace
Sep 17, 26
Goa Therapeutics launches with ‘immeasurably huge’ vision of creating Narcan for alcohol
fiercebiotech
Aug 28, 26
Why Roche is 'really excited' about a UCN2 analog for obesity after seeing preclinical data
fiercebiotech
← prev
page 1 of 2
next →